someone else found this, i am just posting it on this forum...
this paper seems to be sayying that nystatin may have antiretroviral effects
http://www.clinicaltrialssearch.org/a-study-of-nystatin-in-hiv-infected-patients-nct00002313.html
AIDS Res Hum Retroviruses. 1993 May;9(5):475-81.
Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Selvam MP, Blay RA, Geyer S, Buck SM, Pollock L, Mayner RE, Epstein JS.Laboratory of Immunochemistry, Food and Drug Administration, Rockville, MD 20852.
Nystatin A was compared in vitro with amphotericin B, AZT, or foscarnet for their respective abilities to inhibit the replication of human immunodeficiency virus type 1 (HIV-1) in H9 cells. HIV-1-infected H9 cells were cultured for 7 days in the presence of each of these drugs, at various concentrations. Reverse transcriptase activity and p24 antigen production were quantitated. Untreated, HIV-1-infected H9 cells served as the control. Nystatin A inhibited viral replication most effectively at 10 micrograms/ml, a concentration that did not affect cell viability. Nystatin-A treatment inhibited RT activity by 85% and p24 production by 90%. These levels of inhibition were comparable to that mediated by amphotericin B, AZT, or foscarnet at 10, 25, and 50 micrograms/ml, respectively. Western blot analysis of the HIV-1-infected H9 cells treated with these drugs did not detect any expression of viral proteins. These findings were further corroborated by indirect immunofluorescence studies using monoclonal anti-gp120 FITC-conjugated antibodies and by polymerase chain reaction for proviral DNA analysis, using a 32P-labeled probe. These results suggest that Nystatin A merits attention as an antiviral drug for the treatment of HIV-1 infection. In vivo drug delivery by liposome encapsulation to overcome problems of bioavailability is currently under study. PMID: 7686387
this paper seems to be sayying that nystatin may have antiretroviral effects
http://www.clinicaltrialssearch.org/a-study-of-nystatin-in-hiv-infected-patients-nct00002313.html
AIDS Res Hum Retroviruses. 1993 May;9(5):475-81.
Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Selvam MP, Blay RA, Geyer S, Buck SM, Pollock L, Mayner RE, Epstein JS.Laboratory of Immunochemistry, Food and Drug Administration, Rockville, MD 20852.
Nystatin A was compared in vitro with amphotericin B, AZT, or foscarnet for their respective abilities to inhibit the replication of human immunodeficiency virus type 1 (HIV-1) in H9 cells. HIV-1-infected H9 cells were cultured for 7 days in the presence of each of these drugs, at various concentrations. Reverse transcriptase activity and p24 antigen production were quantitated. Untreated, HIV-1-infected H9 cells served as the control. Nystatin A inhibited viral replication most effectively at 10 micrograms/ml, a concentration that did not affect cell viability. Nystatin-A treatment inhibited RT activity by 85% and p24 production by 90%. These levels of inhibition were comparable to that mediated by amphotericin B, AZT, or foscarnet at 10, 25, and 50 micrograms/ml, respectively. Western blot analysis of the HIV-1-infected H9 cells treated with these drugs did not detect any expression of viral proteins. These findings were further corroborated by indirect immunofluorescence studies using monoclonal anti-gp120 FITC-conjugated antibodies and by polymerase chain reaction for proviral DNA analysis, using a 32P-labeled probe. These results suggest that Nystatin A merits attention as an antiviral drug for the treatment of HIV-1 infection. In vivo drug delivery by liposome encapsulation to overcome problems of bioavailability is currently under study. PMID: 7686387
